Clinical trial
Prognostic Value of Soluble Urokinase Plasminogen Activation Receptor (SUPAR) to Rule Out Complications in Patients Admitted in Emergency Department for Acute Abdominal Pain.
NCT05580016 is registered in ClinicalTrials.gov with Poitiers University Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Prognostic Value of Soluble Urokinase Plasminogen Activation Receptor (SUPAR) to Rule Out Complications in Patients Admitted in Emergency Department for Acute Abdominal Pain.
- Lead sponsor
- Poitiers University Hospital
- Phase
- Observational
- Overall status
- Completed
- Start date
- January 9, 2023
- Completion date
- December 27, 2023
- Enrollment
- 200 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
abdominal pain, emergency department, mortality, soluble urokinase plasminogen activation receptor